CasNo.163222-33-1,factory supply GMP,DMF,CEP Ezetimibe,(163222-33-1) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: USP/EP/BP
Payment Terms : L/C,T/T,Other

Keywords

Ezetimibe Ezatimibe 163222-33-1

Quick Details

Appearance:White crystallization
Application:anti-hyperlipidemic
PackAge:25kg/drum
ProductionCapacity:10|Metric Ton|Day
Storage:room temperature
Transportation:AIR SEA TRAIN

Superiority:

We are very compeitive on Ezetimibe.Our mfr is GMP certified for this item with CEP document.

Product Name:	Ezetimibe
CAS:	163222-33-1
MF:	C24H21F2NO3
MW:	409.43
EINECS:	682-606-0
Product Categories:	Isotope;CEDAX;Final material;API;Cardiovascular APIs;Ezetimibe;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals

Details:

Ezetimibe Chemical Properties

Melting point	164-166°C
alpha	D22 -33.9° (c = 3 in methanol)
Boiling point	654.9±55.0 °C(Predicted)
density	1.334±0.06 g/cm3(Predicted)
storage temp.	2-8°C
form	powder
pka	9.72±0.30(Predicted)
CAS DataBase Reference	163222-33-1(CAS DataBase Reference)
EPA Substance Registry System	2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (163222-33-1)

Ezetimibe Usage And Synthesis

Description

Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol.

Indications and Usage

Ezetimibe is a new form of selective cholesterol absorption inhibitor developed in a collaboration between Schering-Plough Co. and Merck Co. This drug is the first cholesterol absorption selective inhibitor to be approved for sale by the American FDA. Its commercial name is Ezetrol.
This drug can be used alone or in combination with HMG-CoA reductase inhibitors (statins) to treat primary (heterozygous familial and non-familial) hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), homozygous viremia (or phytosterolemia).